CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued
PharmaCompass is introducing a new regulatory update
that tracks developments in Certificates of Su
DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions
The
third quarter (Q3) of 2025 witnessed a steady rise in Drug Master File (DMF) submissions to the
FDA’s first generic approvals slump 21% in 2024; Novartis’ top seller Entresto, cancer blockbuster Tasigna lead 2024 patent cliff
A watershed moment in the journey of a drug is when it transitions from being a patented, high‐
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.